Diabetes Mellitus, Type 2

Metabolic Diseases
291
Pipeline Programs
30
Companies
50
Clinical Trials
3 recruiting
26
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
76
0
42
7
106
60
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
7660%
Small Molecule
5140%
+ 272 programs with unclassified modality

On Market (26)

Approved therapies currently available

Takeda
ACTOSApproved
pioglitazone
Takeda
oral1999
Sanofi
ADLYXINApproved
lixisenatide
Sanofi
subcutaneous2016
Sanofi
APIDRAApproved
insulin glulisine
Sanofi
Insulin Analog [EPC]intravenous, subcutaneous2004
Sanofi
APIDRA SOLOSTARApproved
insulin glulisine
Sanofi
Insulin Analog [EPC]subcutaneous2004
U
DAPAGLIFLOZINApproved
dapagliflozin
Unknown Company
oral
U
EMPAGLIFLOZINApproved
empagliflozin
Unknown Company
oral2022
AstraZeneca
FARXIGAApproved
dapagliflozin
AstraZeneca
oral2014
U
GLIMEPIRIDEApproved
glimepiride
Unknown Company
Sulfonylurea [EPC]oral2009
M&
JANUVIAApproved
sitagliptin
Merck & Co.
oral2006
Boehringer Ingelheim
JARDIANCEApproved
empagliflozin
Boehringer Ingelheim
Sodium-Glucose Cotransporter 2 Inhibitor [EPC]oral2014
Takeda
KAZANOApproved
alogliptin and metformin hydrochloride
Takeda
oral2013
Sanofi
LANTUSApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
Sanofi
LANTUS SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
U
LINAGLIPTINApproved
linagliptin
Unknown Company
oral2025
Boehringer Ingelheim
MICARDISApproved
telmisartan
Boehringer Ingelheim
Angiotensin 2 Receptor Blocker [EPC]oral1998
Novo Nordisk
OZEMPICApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2017
Novo Nordisk
RYBELSUSApproved
semaglutide
Novo Nordisk
oral2020
U
SITAGLIPTINApproved
sitagliptin
Unknown Company
film coated
Novartis
STARLIXApproved
nateglinide
Novartis
oral2000
Sanofi
TOUJEO MAX SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015
Sanofi
TOUJEO SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015
Boehringer Ingelheim
TRADJENTAApproved
linagliptin
Boehringer Ingelheim
Dipeptidyl Peptidase 4 Inhibitor [EPC]oral2011
Novo Nordisk
TRESIBAApproved
insulin degludec
Novo Nordisk
Insulin Analog [EPC]subcutaneous2015
Eli Lilly and Company
TRULICITYApproved
dulaglutide
Eli Lilly and Company
GLP-1 Receptor Agonist [EPC]injection2014
Novo Nordisk
WEGOVYApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2021
U
ZITUVIOApproved
sitagliptin
Unknown Company
Dipeptidyl Peptidase 4 Inhibitor [EPC]oral2023

Competitive Landscape

41 companies ranked by most advanced pipeline stage

Novo Nordisk
146 programs
32
10
1
28
10
Insulin degludecPhase 41 trial
Insulin icodecPhase 41 trial
SemaglutidePhase 4Peptide1 trial
SemaglutidePhase 4Peptide1 trial
SemaglutidePhase 4Peptide1 trial
+141 more programs
Active Trials
NCT04883086Completed182Est. Nov 2021
NCT03862690Withdrawn0Est. Jun 2021
NCT04216875Completed738Est. Dec 2020
+143 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
99 programs
16
11
36
7
EmpagliflozinPhase 4Small Molecule1 trial
EmpagliflozinPhase 4Small Molecule1 trial
EmpagliflozinPhase 4Small Molecule1 trial
TelmisartanPhase 4Small Molecule1 trial
empagliflozin 10mgPhase 41 trial
+94 more programs
Active Trials
NCT04295005Completed24,500Est. Sep 2021
NCT03363464Active Not Recruiting230,000Est. Apr 2026
NCT05465317Completed62,197Est. May 2023
+96 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
28 programs
10
3
2
8
2
GlimepiridePhase 45 trials
TRULICITY(dulaglutide)Phase 4Peptide5 trials
BI 10773Phase 3
Human Insulin Inhalation PowderPhase 31 trial
LY2189265Phase 31 trial
+23 more programs
Active Trials
NCT01055808Completed677Est. Nov 2010
NCT04974333Unknown1,512Est. Feb 2024
NCT01667900Completed58Est. Jun 2014
+26 more trials
Sanofi
15 programs
1
4
6
INSULIN GLARGINEPhase 41 trial
Insulin GlarginePhase 41 trial
Insulin glarginePhase 41 trial
Insulin glarginePhase 41 trial
Lantus®Phase 41 trial
+10 more programs
Active Trials
NCT01065909Completed3,491Est. Sep 2014
NCT00174668Completed311
NCT00713830Completed859Est. Jan 2011
+7 more trials
Abbott
AbbottABBOTT PARK, IL
12 programs
2
3
1
daily enteral nutritional product and/or behavioral changesPhase 41 trial
Experimental nutritional formula #M979Phase 31 trial
Nutritional FormulaPhase 31 trial
standard nutritional productPhase 31 trial
Carbohydrate placeboPhase 2/31 trial
+7 more programs
Active Trials
NCT01390610Completed27Est. Jan 2013
NCT06632002Active Not Recruiting103Est. May 2026
NCT05802927Completed64Est. Oct 2023
+10 more trials
AstraZeneca
10 programs
1
2
5
1
AC2993Phase 3
GALIDAPhase 31 trial
GalidaPhase 31 trial
TesaglitazarPhase 31 trial
TesaglitazarPhase 31 trial
+5 more programs
Active Trials
NCT01754142Completed755Est. Sep 2016
NCT01192659Completed16,492Est. Dec 2015
NCT00538174Completed36Est. May 2008
+6 more trials
Novartis
NovartisBASEL, Switzerland
8 programs
5
3
NateglinidePhase 41 trial
Nateglinide 120 mgPhase 41 trial
nateglinidePhase 41 trial
vildagliptinPhase 3Small Molecule1 trial
vildagliptinPhase 3Small Molecule1 trial
+3 more programs
Active Trials
NCT00106340Completed3,118Est. May 2008
NCT00260156Completed59Est. Dec 2008
NCT00120536Completed288Est. Jul 2006
+9 more trials
M&
Merck & Co.RAHWAY, NJ
7 programs
1
1
2
1
Metformin IRPhase 41 trial
MK0767Phase 35 trials
sitagliptinPhase 3Small Molecule1 trial
MK0916Phase 21 trial
MK-3102Phase 11 trial
+2 more programs
Active Trials
NCT02757937Completed513Est. Dec 2017
NCT03447275CompletedEst. Sep 2011
NCT01767688Completed16Est. Mar 2013
+8 more trials
Takeda
6 programs
1
3
1
PioglitazonePhase 41 trial
Pioglitazone-AzilsartanPhase 3Small Molecule1 trial
TAK-875Phase 33 trials
TAK-875Phase 31 trial
KAZANO(Alogliptin)Phase 2Small Molecule1 trial
+1 more programs
Active Trials
NCT03487887Completed100Est. Aug 2021
NCT01263470Completed480Est. Dec 2007
NCT01124656Terminated26Est. May 2007
+5 more trials
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
1
Lactulose crystals 20 gPhase 41 trial
Active Trials
NCT03666546Completed24Est. Mar 2019
Celltrion
CelltrionKorea - Incheon
1 program
1
Pioglitazone + AlogliptinPhase 4Small Molecule1 trial
Active Trials
NCT03499704Unknown133Est. Jun 2024
Lantheus Medical Imaging
1 program
1
Technetium Tc99m SestamibiPhase 41 trial
Active Trials
NCT00162357CompletedEst. Dec 2005
Pfizer
10 programs
3
2
3
CP-464,005Phase 31 trial
Health coachingPhase 31 trial
Inhaled Human InsulinPhase 31 trial
Inhaled insulinPhase 21 trial
PF-00915275Phase 21 trial
+5 more programs
Active Trials
NCT00248352Completed212Est. Oct 2007
NCT00541606Completed285Est. Jul 2004
NCT00886821Completed114Est. Jun 2011
+7 more trials
Alkermes
AlkermesDUBLIN 4, Ireland
6 programs
1
1
4
Human Insulin Inhalation PowderPhase 3
Human Insulin Inhalation PowderPhase 3
Human Insulin Inhalation PowderPhase 3
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation PowderPhase 3
Human Insulin Inhalation PowderPhase 2/3
+1 more programs
Bristol Myers Squibb
4 programs
1
1
muraglitazarPhase 35 trials
DapagliflozinPhase 2/3Small Molecule
Extension of CareN/A1 trial
Risk Factors for Low Lymphocyte Count in Patients With Type 2 DiabetesN/A
Active Trials
NCT01965639Completed648Est. Jun 2016
NCT00240370Completed1,159
NCT00162175Completed534Est. Nov 2005
+3 more trials
HM
Hua MedicineChina - Shanghai
3 programs
1
2
HMS5552Phase 31 trial
HMS5552Phase 31 trial
HMS5552Phase 21 trial
Active Trials
NCT02561338Completed258Est. Sep 2016
NCT03173391Completed463Est. Nov 2020
NCT03141073Completed767Est. Feb 2021
R
ResVerlogiXAB - Calgary
1 program
1
ApabetalonePhase 31 trial
Active Trials
NCT02586155Completed2,425Est. Jun 2021
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
1
Inhaled Human InsulinPhase 3
GSK
GSKLONDON, United Kingdom
6 programs
4
2
NC-503Phase 21 trial
SRT2104Phase 21 trial
0.5g SRT2104Phase 11 trial
250 mg SRT2104 SuspensionPhase 11 trial
SRT2104Phase 11 trial
+1 more programs
Active Trials
NCT00938275Completed20Est. Mar 2009
NCT00937872Completed9Est. Dec 2008
NCT00933530Completed43Est. Nov 2008
+3 more trials
Opko Health
Opko HealthMIAMI, FL
3 programs
1
2
LY2944876Phase 21 trial
TT223 with Metformin and/or TZDPhase 21 trial
LY2428757Phase 1
Active Trials
NCT02119819CompletedEst. Oct 2015
NCT00743002CompletedEst. Dec 2009
Astellas
AstellasChina - Shenyang
1 program
1
ASP1941Phase 25 trials
Active Trials
NCT01097681Completed25Est. Jun 2010
NCT01099839Completed30Est. Apr 2010
NCT01302028Completed40Est. Jun 2010
+2 more trials
DS
1
CS-917Phase 21 trial
Active Trials
NCT00290940Completed400Est. Apr 2007
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
GWP42004Phase 21 trial
Active Trials
NCT02053272Completed207Est. Feb 2016
MediciNova
MediciNovaLA JOLLA, CA
1 program
1
MN-001Phase 21 trial
Active Trials
NCT05464784Active Not Recruiting40Est. Dec 2026
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
RanolazinePhase 21 trial
Active Trials
NCT01163721Completed80Est. Nov 2010
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
5 programs
5
Canagliflozin 50 mgPhase 13 trials
JNJ 28431754Phase 11 trial
JNJ-38431055Phase 12 trials
JNJ-38431055 Dose 1Phase 11 trial
JNJ-38431055; PlaceboPhase 11 trial
Active Trials
NCT02846506Completed44Est. Oct 2016
NCT01281579Completed27Est. Apr 2011
NCT01128985Completed39Est. Jul 2010
+5 more trials
CT
1
AP026Phase 11 trial
Active Trials
NCT06143423UnknownEst. Dec 2024
Akros Pharma
1 program
1
JTT-662Phase 11 trial
Active Trials
NCT04465877Completed37Est. Feb 2021
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
REGN1193Phase 11 trial
Active Trials
NCT02284425Terminated72Est. Dec 2015
Fractyl Health
Fractyl HealthMA - Burlington
4 programs
DMR ProcedureN/A1 trial
DMR ProcedureN/A1 trial
Duodenal Mucosal ResurfacingN/A1 trial
Revita® DMR TreatmentN/A1 trial
Active Trials
NCT02413567CompletedEst. Sep 2019
NCT02879383CompletedEst. Dec 2019
NCT06256497SuspendedEst. Dec 2028
+1 more trials

+11 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Novo NordiskInsulin icodec
Novo NordiskSemaglutide Auto-Injector
SanofiMethodological intervention
Novo NordiskSemaglutide Oral Tablet
Eli Lilly and Companydulaglutide
Eli Lilly and Companydulaglutide
Novo NordiskSemaglutide
Novo NordiskSemaglutide Pill
Novo Nordisksemaglutide
Novo NordiskSemaglutide
Boehringer IngelheimEmpagliflozin
CelltrionPioglitazone + Alogliptin
Eli Lilly and Companydulaglutide
Fresenius KabiLactulose crystals 20 g
Eli Lilly and Companydulaglutide

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 32,000 patients across 50 trials

A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

Start: Aug 2025Est. completion: Aug 2028586 patients
Phase 4Recruiting
NCT05780905Novo NordiskSemaglutide Auto-Injector

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

Start: Jan 2024Est. completion: Dec 202650 patients
Phase 4Recruiting
NCT05780151SanofiMethodological intervention

Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)

Start: Jul 2023Est. completion: Jan 2025107 patients
Phase 4Completed
NCT05441267Novo NordiskSemaglutide Oral Tablet

A Study of Cardiovascular Events iN Diabetes Plus

Start: Mar 2023Est. completion: Aug 204820,000 patients
Phase 4Recruiting

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

Start: Dec 2022Est. completion: Jan 2024212 patients
Phase 4Completed

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Start: Nov 2022Est. completion: Aug 2024282 patients
Phase 4Completed

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

Start: Apr 2022Est. completion: Jan 2024104 patients
Phase 4Completed
NCT04938388Novo NordiskSemaglutide Pill

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

Start: Jan 2022Est. completion: Feb 202312 patients
Phase 4Terminated

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

Start: Sep 2021Est. completion: Jun 20251,020 patients
Phase 4Completed

Treatment of GLP-1 for Diabetic Bariatric Patients

Start: Aug 2021Est. completion: Aug 20223 patients
Phase 4Terminated

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Start: Oct 2020Est. completion: Aug 2022129 patients
Phase 4Completed
NCT03499704CelltrionPioglitazone + Alogliptin

A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

Start: Feb 2020Est. completion: Jun 2024133 patients
Phase 4Unknown

Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)

Start: Sep 2019Est. completion: Mar 202493 patients
Phase 4Unknown
NCT03666546Fresenius KabiLactulose crystals 20 g

Blood Glucose Response After Oral Intake of Lactulose in Mildly Constipated Patients With Diabetes Mellitus Type 2

Start: Nov 2018Est. completion: Mar 201924 patients
Phase 4Completed

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

Start: Oct 2018Est. completion: Apr 2019312 patients
Phase 4Completed
NCT03687827Novo NordiskInsulin degludec

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study

Start: Oct 2018Est. completion: Dec 2019498 patients
Phase 4Completed

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Start: Jul 2018Est. completion: Jun 20231,278 patients
Phase 4Completed

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

Start: Oct 2017Est. completion: Feb 201812 patients
Phase 4Completed

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

Start: Oct 2016Est. completion: Aug 2020144 patients
Phase 4Completed

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Start: Aug 2016Est. completion: Jun 2018159 patients
Phase 4Completed

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Start: Oct 2015Est. completion: Jun 201765 patients
Phase 4Completed

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Start: Oct 2015Est. completion: Jan 2018269 patients
Phase 4Completed

Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes

Start: Dec 2014Est. completion: Apr 2016
Phase 4Completed

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Start: Jun 2014Est. completion: Oct 201770 patients
Phase 4Completed

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Start: Feb 2014Est. completion: Oct 2015192 patients
Phase 4Terminated

Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride

Start: Jan 2014Est. completion: Feb 201640 patients
Phase 4Completed

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

Start: Jul 2013Est. completion: Sep 201495 patients
Phase 4Terminated

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Start: Jul 2013Est. completion: May 201650 patients
Phase 4Completed

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Start: May 2013Est. completion: Oct 2015117 patients
Phase 4Completed

Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function

Start: Nov 2012Est. completion: Sep 201451 patients
Phase 4Completed

Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.

Start: Aug 2012Est. completion: Oct 2013162 patients
Phase 4Completed

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Start: Feb 2012Est. completion: Dec 20133,091 patients
Phase 4Completed

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Start: Jan 2012Est. completion: Apr 2013316 patients
Phase 4Completed

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Start: Nov 2011Est. completion: Mar 2013689 patients
Phase 4Completed

Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

Start: Nov 201144 patients
Phase 4Unknown

Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy

Start: Jun 2011Est. completion: Jun 2012187 patients
Phase 4Completed

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Start: Feb 201124 patients
Phase 4Completed

Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Start: Oct 2010Est. completion: Apr 2011150 patients
Phase 4Completed

Phase 4 Study in the Elderly Patients With T2DM

Start: Oct 2010Est. completion: Dec 201146 patients
Phase 4Completed

Glycemic Holter Study (Continuous Glucose Monitoring) -

Start: Jun 2010Est. completion: Jun 201136 patients
Phase 4Completed

Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus

Start: Apr 2010Est. completion: Nov 201044 patients
Phase 4Completed
NCT01081938SanofiINSULIN GLARGINE

Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition

Start: Feb 2010Est. completion: Feb 201115 patients
Phase 4Terminated

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Start: Dec 2009Est. completion: Feb 2011103 patients
Phase 4Completed
NCT00928889NovartisNateglinide 120 mg

Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors

Start: Jul 2009Est. completion: Jun 2010160 patients
Phase 4Completed
NCT00701831SanofiInsulin glargine

Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control

Start: May 2008Est. completion: Oct 2010241 patients
Phase 4Completed
NCT00402012TakedaPioglitazone

"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

Start: Nov 2006Est. completion: Dec 200724 patients
Phase 4Completed
NCT00347100SanofiInsulin Glargine

Insulin Glargine in Type 2 Diabetic Patients

Start: Jun 2006387 patients
Phase 4Completed
NCT00543621Abbottdaily enteral nutritional product and/or behavioral changes

An Intervention Program to Control Diabetes

Start: May 2005150 patients
Phase 4Completed
NCT00162357Lantheus Medical ImagingTechnetium Tc99m Sestamibi

Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty

Start: Apr 2004Est. completion: Dec 2005
Phase 4Completed

A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

Start: May 2003Est. completion: Jun 200524 patients
Phase 4Completed

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

106 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 32,000 patients
30 companies competing in this space